Semaglutide improves heart health and reduces weight in obese patients, but with side effects
Semaglutide significantly reduces cardiovascular events and adverse effects in overweight and obese patients. The study highlights semaglutide’s superiority over other GLP-1 agonists for cardiovascular health.